Offering
Offering
Integrated Biologics
Integrated Biologics
Expression Technologies
Expression Technologies
GS Xceed® Gene Expression System
GS piggyBac® Transposon Technology
GS Effex® Cell Line
GS Discovery® Transient Expression
bYlok® Bispecific Pairing Technology
XS Technologies®
Technical Support
Early Derisking and Optimization
Early Derisking and Optimization
Developability Assessment
Manufacturability Assessment
Antibody Humanization and Deimmunization
Protein Engineering
Potency Assessment
Immunogenicity / Immunotoxicity Assessment
Rapid Host Screen and Early Protein Expression
Non-GMP Manufacture
Epibase® in vitro and in silico Screening
Mammalian Biopharmaceutical Services
Mammalian Biopharmaceutical Services
Ibex® Design mAbs DNA-to-IND Program
Ibex® Design Bispecifics DNA-to-IND Program
Ibex® Design Fabs and Fc-Fusion Proteins DNA-to-IND Programs
Ibex® Design Scaffolds and other Recombinant Proteins
Cell Line Development
Tailored License Application Program
Process Development
Analytical Development
Drug Substance Manufacturing
Parenteral Drug Product Services
Parenteral Drug Product Services
Clinical Technology Transfers
Biologics Formulatability
Product Formulation Development
Analytical Development
Process Development
Biologics Special Services
Drug Product Manufacture
Biologics Regulatory Services
Knowledge Center
Advanced Synthesis
Advanced Synthesis
Small Molecules
Small Molecules
Drug Substance/API Services
Drug Substance/API Services
API Support for Early Phase Development
AI-Enabled Route Scouting Service
Solid Form Drug Services
PBPK Modeling Services
Pharmaceutical Method Development
Commercial API Manufacturing Services
Highly Potent API Technologies
Highly Potent API Technologies
HPAPI Handling and Development
HPAPI Manufacturing | Low & High Potency
ADC Clinical and Commercial Manufacturing
ADC Payload Product Development
Particle Engineering
Particle Engineering
Solid Dispersion Technology
Bioavailability Enhancement
Spray-Dried Dispersion Technology
Micronization and Jet Milling
Hot Melt Extrusion
Drug Product
Drug Product
SimpliFiH® Solutions
Drug Product Technologies
Drug Product Technologies
Specialized Drug Product Development
Micro-dosing for Early Human Clinical Studies
Clinical Trial Material Manufacture, Supply
Clinical Bottling, Labelling and Supply
Formulation and Development
Design and Preformulation Development
Drug Development Workflow & Pharmaceutical Process Optimization
Pediatric Drug Product Development
Inhalation Formulation Development
Integrated Offerings
Regulatory Affairs CMC Services
Regulatory Affairs CMC Services
CMC Development Services | CMC Regulatory Submissions
Bioconjugates Services
Bioconjugates Services
Early Development Bioconjugates | ADCs
ADC Drug Substance Manufacturing
Pharmaceutical, ADC Analytical Services
Targeting Agent and Carrier Protein
ADC Process Development
Ibex® Design ADC, DNA-to-IND Program
Knowledge Center
Specialized Modalities
Specialized Modalities
Cell & Gene
Cell & Gene
Process Development
cGMP Manufacturing
Allogeneic
Autologous
Viral Vectors
Exosomes
Cocoon® Platform
Microbial
Microbial
Microbial Strain Development
Process Development
Drug Substance Manufacturing
Analytical Development
mRNA/LNP
mRNA/LNP
Process Development
Analytical Services
mRNA Manufacturing
Lipid Nanoparticles Encapsulation
Bioscience Products
Knowledge Center
Knowledge Center
Company
Company
About Us
About Us
Our One Lonza Strategy
Our Leadership
Our Leadership
Executive Committee
Board of Directors
Board Committees
Our History
Our Locations
News and Media
News and Media
News Releases
Images and Videos
Logo Guidelines
Blog
A View On - Lonza Podcast
Journalist Inquiries
Investor Relations
Investor Relations
Shareholders and Stock Information
Shareholders and Stock Information
Consensus and Analysts
Bond Investors and Credit Information
Investor FAQ
Share Buyback
Agenda and Events
Reporting and Presentations
Corporate Governance
Ethics and Compliance
Investor Inquiries
Sustainability
Sustainability
Environment
People and Society
Compliance and Integrity
Responsible Sourcing
Global Quality
Careers
Careers
Welcome to Lonza
Life at Lonza
Employee Benefits
Early Career Opportunities
Inclusion, Diversity and Belonging
Join Our Talent Community
Contact
Cancel
Restored archive imagery
Lonza began making nitric acid for fertilizers in 1927
Lonza’s facilities expanded in the Valais as the business continued to develop in the first half of the Twentieth Century
Lonza produced hydroelectricity from the River Lonza
Lonza’s early beginnings in the Swiss Alps
Lonza’s second site in Visp
Lonza’s hydroelectricity power station in Gampel
A sorting facility for fertilizer in Gampel
At times, fertilizer bags were stacked up to 40 levels high
Reckingen Kraftwerk was a low-pressure hydroelectric power plant in a shallow section of the Rhine, which was completed in 1942
Early workers at Lonza, est.1915
Lonza’s first shipment of Acetic acid, an important chemical reagent
In the 1930s and 40s, Lonza developed sophisticated products for specific crops
An early image of Lonza’s site in Gampel, adjacent to the River Lonza
Lonza’s exhibited fertilizers at industry events, such as this one in Lausanne est. 1933
Hydroelectricity was a major source of power in the early Twentieth Century and remains a major source of renewable energy in Switzerland today
Lonza’s first site in Gampel was adjacent to the River Lonza, after which the company is named
For 125 years, Lonza’s people have adapted to work with new technology and innovations
Lonza’s pioneering approach to technological innovation has been a major driver of competitive advantage
The construction of large dams helped to harness hydropower, a major source of electricity in Switzerland in the Twentieth Century
Lonza’s fertilizers supported food security in Switzerland during the wartime years
A Lonza worker monitoring the manufacturing facility
Alfons Ehinger, the first President of Lonza
Lonza was established to harness the hydroelectric power of the River Lonza for the manufacture of calcium carbide
Lonza built hydroelectric plants in the Swiss valleys in the late 1800s
Large, heavy and industrial goods were often moved by rail
By the mid-Twentieth Century, Lonza was a major player in chemical manufacture
Lonza’s site in Gampel used energy from hydropower to produce calcium carbide, a critical source of light at the turn of the Twentieth Century
An early look inside Lonza’s Gampel hydropower facility
Lonza Gampel, 1916
Colleagues producing carbide in Gampel, 1916
An early image of Lonza’s first site in Gampel, est. 1899
A component for the construction of the Reckingen hydropower plant, 1941
Visp, 1909
Fertilizer production in the 1930s
Cookie Settings
|
Terms and Conditions
|
Legal Disclaimer
|
Privacy Policy